BioMarin Pharmaceutical (BMRN) Stock
NSQ · BMRN
59.51
Fundamentals
Market cap
$11.66B
Price / Earnings ratio
162.7x
Price / Sales ratio
3.5x
Price / Book ratio
1.9x
Return on assets
3.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
NeutralBMRNSeptember 18, 2026
MarketBeatNeutral
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BMRN

Zacks Investment Research
BioMarin Stops Voxzogo Development for Noonan Syndrome
NeutralBMRNSeptember 16, 2026
Zacks Investment ResearchNeutral
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN

Stocktwits
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
NeutralBMRNSeptember 4, 2026
StocktwitsNeutral
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
BMRN

Zacks Investment Research
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
NeutralBMRNSeptember 3, 2026
Zacks Investment ResearchNeutral
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral2
Buy8
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
4B3B1B0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
9B6B3B0
Revenue to Profit
2025$3.2B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$348.9M
Net incomeEarnings
EPS forecast
Actual EPS
$1.44
$0.93
Q2FY25
$0.12
$0.51
Q3FY25
$0.86
Q4FY25
$1.19
Q1FY26
$1.14
Q2FY26
The market is expecting earnings per share of $1.14 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
NeutralBMRNSeptember 18, 2026
MarketBeatNeutral
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BMRN

Zacks Investment Research
BioMarin Stops Voxzogo Development for Noonan Syndrome
NeutralBMRNSeptember 16, 2026
Zacks Investment ResearchNeutral
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN

Stocktwits
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
NeutralBMRNSeptember 4, 2026
StocktwitsNeutral
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
BMRN

Zacks Investment Research
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
NeutralBMRNSeptember 3, 2026
Zacks Investment ResearchNeutral
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN

Zacks Investment Research
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
NeutralBMRNSeptember 1, 2026
Zacks Investment ResearchNeutral
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
BMRN

Stocktwits
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
NeutralBMRNAugust 31, 2026
StocktwitsNeutral
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
BMRN

Zacks Investment Research
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
NeutralBMRNAugust 19, 2026
Zacks Investment ResearchNeutral
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
BMRN

CNBC
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
NeutralBMRNAugust 19, 2026
CNBCNeutral
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BMRN

Stocktwits
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why
NeutralBMRNAugust 18, 2026
StocktwitsNeutral
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why
BMRN

Zacks Investment Research
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
NeutralBMRNAugust 14, 2026
Zacks Investment ResearchNeutral
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
BMRN
About BioMarin Pharmaceutical
BioMarin is a world leader in developing and commercializing therapies for rare genetic diseases. We take pride in going where the science leads us, pioneering breakthrough treatments for debilitating and life-threatening conditions where we can significantly improve upon the current standard of care.
SectorHealthcare
IndustryBiotechnology
Employees3,221
CEOMr. Alexander Hardy
IPO DateJul 23, 1999
HeadquartersSan Rafael, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Alexander Hardy | President, CEO & Director | 1969 |
| Mr. Brian R. Mueller CPA | CFO & Executive VP of Finance | 1974 |
| Dr. C. Greg Guyer Ph.D. | Executive VP & CTO | 1962 |
| Ms. Cristin Hubbard | Executive VP & Chief Commercial Officer | — |
| Dr. Gregory Friberg M.D. | Executive VP and Chief Research & Development Officer | — |
| Ms. Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer | 1979 |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development | — |
| Mr. Arpit Dave | Executive Vice President, Chief Digital & Information Officer | — |
| Mr. George Eric Davis J.D. | Executive VP, Chief Legal Officer & Secretary | 1971 |
| Ms. Amy Wireman | Executive VP & Chief People Officer | — |
Fundamentals
Valuation
Market cap$11.66B
Price-to-sales ratio3.49
Price-to-book value1.88
Price-earnings ratio162.70
Return on Equity4.00%
Return on Sales13.00%
Return on Assets3.00%
PEG ratio0.68
Earnings Per Share
Earnings Per Share$0.38
Income Statement
Average volume1,912,085
EBITDA$482.49M
1 year high (52w)$70.98
1 year low (52w)$49.26
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
10 Wall Street Analyst Ratings
BUY
80% Buy
20% Hold
0% Sell
Target price
$93.70
Est return
55.49%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.7 | +2.7 | +5.2 | +4.6 | ||||||||
| 2022 | -0.8 | -12.7 | -0.3 | +2.6 | -9.8 | +11.4 | +1.3 | +4.4 | -6.7 | -0.1 | +16.6 | +0.5 |
| 2023 | +14.7 | -14.7 | -3.7 | -0.6 | -10.4 | -1.8 | +2.4 | +2.7 | -4.9 | -6.5 | +8.4 | +4.3 |
| 2024 | -10.2 | -2.8 | +0.2 | -7.3 | -9.9 | +7.7 | +2.7 | +7.8 | -23.3 | -6.0 | -0.9 | +1.1 |
| 2025 | -4.7 | +14.0 | -0.5 | -6.3 | -7.4 | -3.6 | +3.0 | +0.2 | -8.3 | -2.4 | +5.8 | +8.0 |
| 2026 | -4.9 | +6.5 | -5.4 | -5.8 | +6.0 | +4.0 | +3.8 | +8.7 | -7.1 |



